Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2001-09-13
2003-07-29
Richter, Johann (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S562000, C514S563000, C514S564000, C514S566000, C560S151000, C560S152000, C560S155000, C560S169000, C560S171000, C562S557000, C562S571000, C562S573000
Reexamination Certificate
active
06599940
ABSTRACT:
BACKGROUND OF THE INVENTION
Glutamic acid is one of the 20 amino acids commonly found in animal proteins. Only the L-stereoisomer occurs in mammalian proteins. Like aspartic acid, glutamic acid has an acidic carboxyl group on its side chain which can serve as both an acceptor and a donor of ammonia, a compound toxic to the body. Once glutamic acid has coupled with ammonia, it is called glutamine and can as such safely transport ammonia to the liver, where the ammonia is eventually converted to urea for excretion by the kidneys. Free glutamic acid (that not incorporated into proteins) can also be converted reversibly to &agr;-ketoglutaric acid, an intermediate in the Krebs cycle, and as such can be degraded to carbon dioxide and water, or transformed into sugars. The acidic side chain of glutamic acid confers one negative charge under most conditions to proteins in which this amino acid is found, thus increasing the water solubility of the protein. Monosodium glutamate (MSG), the monosodium salt of L-glutamic acid, is widely used as a condiment. The amino acid was isolated from wheat gluten in 1866 and chemically synthesized in 1890. It is not essential to the human diet, since it can be synthesized in the body from the common intermediate &agr;-ketoglutaric acid.
The fluid produced by the prostate gland contains significant amounts of glutamic acid, and this amino acid may play a role in normal function of the prostate. In one study, symptoms of benign prostatic hyperplasia (BPH) were improved in a group of forty-five men taking 780 mg of glutamic acid per day for two weeks and then 390 mg for the next two and a half months in combination with equal amounts of the amino acids alanine and glycine, an effect also reported by other researchers. See Damrau, F. “Benign prostatic hypertrophy: Amino acid therapy for symptomatic relief”,
J. Am Geriatr Soc
1962; 10(5):426-30; and Feinblatt, H. M. and Gant, J. C. “Palliative treatment of benign prostatic hypertrophy. Value of glycine-alanine-glutamic acid combination”,
J. Maine Med Assoc
March 1958.
L-Glutamate is one of the most abundant excitatory amino acid neurotransmitters found in the mammalian brain. This amino acid acts on diverse glutamate receptors including members of both the ionotropic and metabotropic glutamate receptor (mGluR) families. Bräuner-Osborne, H.; Egebjerg, J.; Nielsen, E.; Madsen, U.; Krogsgaard-Larsen, P.
J. Med. Chem.
2000, 43, 2609; and Nakanishi, S.
Science
1992, 258, 597; Blasi, A. D.; Conn, P. J.; Pin, J. P.; Nicoletti, F.
Trends Pharmacol. Sci.
2001, 22, 114. Because of the possibility to identify ligands that may prove useful in disease intervention, considerable attention has been given to the discovery of both selective agonists and antagonists of these glutamate receptors over the past decade. Mukhopadhyaya, J. K.; Kozikowski, A. P.; Grajkowska, W.; Pshenichkin, S.; Wroblewski, J. T.
Bioorg. Med. Chem. Lett
., in press; Kozikowski, A. P.; Steensma, D.; Araldi, G. L.; Pshenichkin, S.; Surina, S.; Wroblewski, J. T.
J. Med. Chem.
1998, 41, 1641.
SUMMARY OF THE INVENTION
One aspect of the present invention relates to 2-hydroxymethylglutamic acid and congeners thereof. A second aspect of the invention relates to a method of synthesizing 2-hydroxymethylglutamic acid and congeners thereof.
REFERENCES:
patent: 4935534 (1990-06-01), Scholl
patent: 5190922 (1993-03-01), Luly et al.
patent: 5362899 (1994-11-01), Campbell
patent: 5686565 (1997-11-01), Kyle et al.
patent: 5780589 (1998-07-01), Lazarus et al.
patent: 5880096 (1999-03-01), Barrett et al.
patent: 5932549 (1999-08-01), Allen et al.
patent: 6133018 (2000-10-01), Wu et al.
patent: 6133409 (2000-10-01), Salvino et al.
patent: 6200969 (2001-03-01), Fritz et al.
patent: 6242422 (2001-06-01), Karanewsky et al.
patent: 6291640 (2001-09-01), Bailey et al.
patent: 5 32697 (1993-02-01), None
patent: WO 92/02257 (1992-02-01), None
patent: WO 93/23383 (1993-11-01), None
Schellenberger et al, Theory of Thiamine Pyrophosphate Activity. VIII. Significance of the Intercyclic Methylene Bridge for Thiamine Pyrophosphate Activity, 1988, Hoppe-Seyler's Z. Physiol. Chem., 349(4), pp. 517-518. Abstract Only.*
Greene, Protective Groups in Organic Chemistry, 1986, John Wiley & Sons, New York, pp. 14-16 and 154-159.*
Cagnon et al.; “Unusual Regiochemistry of Cycloaddition of Ketenes to ®-2-tert-Butyldihydrooxazole Derivatives. A Simple Route towards Enantiomerically Pure Functionalised &agr;-Aminocyclobutanones”, Tetrahedron Letters, 38(13): 2291-2294, (1997).
Escribano et al.; “(2S,4S)-2-AMINO-4-(2,2-Diphenylethyl) Pentanedioic Acid Selective Group 2 Metabotropic Glutamate Receptor Antagonist”, Bioorganic & Medicinal Chemistry Letters 8: 765-770, (1998).
Osborne et al.; “Ligands For Glutamate Receptors: Design and Therapeutic Prospects”, Journal of Medicinal Chemistry, 43(14): 2609-2645 (Jul. 13, 2000).
Seebach et al.; 107. Stereoselektive Alkylierung an C(&agr;) von Serin, Glycerinsäure, Threonin und Weinsäure über Heterocyclische Enolate Mit Exocyclischer Doppelbindung1)2), Helvetica Chimica Acta, 70: 1194-1216, (1987) abstract only.
Wünsch et al.; “Stereoselective Synthese Neuer Zentral Wirksamer Tricyclen Vom Benzomorphan-Typ Mit 2-Phenylethylamin Partialstruktur”, Arch. Pharm. (Weinheim)326: 101-113, (1993).
Zhang et al.; “A Teandem Michael Addition Ring-Closure Route to the Metabotropic Receptor Ligand &agr;-(Hydroxymethyl) Glutamic Acid and Its &ggr;-Alkylated Derivatives”, J. Org. Chem. 66: 7555-7559 (2001).
International Search Report Completed on Sep. 17, 2002 and Mailed on Oct. 2, 2002.
Renato et al.; “Unusual Regiochemistry of Cycloaddition of Ketenes to (R)-2-tert-Butyldihydrooxazole Derivatives. A Simple Route Towards Emanttiomerically Pure Functionalised &agr;-Aminocyclobutanones”, Tetrahedron Lettrers 38 (13): 2291-2294, (1997).
Wünsch et al.; “Stereoselektive Synthese Neuer Zentral Wirksamer Tricyclen Vom Benzomorphan-Typ Mit 2-Phenylethylamin Partialstruktur”, Arch. Pharm. (Weinheim) 326:101-113, (1993).
Ezquerra et al.; “Stereoselective Reaction of Lithium Enolates Derived form N-BOC Protected Pyroglutamic Esters”, Tetrahedron 49 (38):8665-8678, (1993).
De Blasi et al.; “Molecular Determinants of Metabotropic Glutamate Receptor Signaling”, Trends in Pharmacological Sciences 22(3): 114-120, (Mar. 2001).
Nakanishi, S. “Molecular Diversity of Glutamate Receptors and Implications for Brain Function”, Science 258: 597-603, (Oct. 23, 1992).
N'Goka et al.; “GABA-Uptake Inhibitors: construction of a General Pharmacophore Model and Successful Prediction of a New Representative”, J. Med. Chem. 34: 2547-2557, (1991).
Kozikowski et al.; “Synthesis and Biology of the Conformationally Restricted ACPD Analogue, 2-Aminobicyclo[2.1.1]hexane-2,5-dicarboxylic Acid-I, a Potent MGluR Agonist”, J. Med. Chem. 41: 1641-1650, (1998).
Escribano et al.; “(2S, 4S)-2-Amino-4-(2,2-Diphenylethyl)Pentanedioic Acid Selective Group 2Metabotropic Glutamate Receptor Antagonist”, Bioorganic & Medicinal chemistry Letters 8:765-770, (1998).
Bräuner-Osborne et al.; “Ligands for Glutamate Receptors: Design and Therapeutic Prospects”, Journal of Medicinal Chemistry, 43(14):2609-2645, (2000).
Foley & Hoag LLP
Georgetown University
Gordon Dana M.
Richter Johann
Zucker Paul A.
LandOfFree
Synthesis of 2-hydroxymethylglutamic acid and congeners thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthesis of 2-hydroxymethylglutamic acid and congeners thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis of 2-hydroxymethylglutamic acid and congeners thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3066390